Literature DB >> 25922088

Effects of AT1 receptor antagonism on kainate-induced seizures and concomitant changes in hippocampal extracellular noradrenaline, serotonin, and dopamine levels in Wistar-Kyoto and spontaneously hypertensive rats.

Jana Tchekalarova1, Ellen Loyens2, Ilse Smolders2.   

Abstract

In the management of epilepsy, AT1 receptor antagonists have been suggested as an additional treatment strategy. A hyperactive brain angiotensin (Ang) II system and upregulated AT1 receptors are implicated in the cerebrovascular alterations in a genetic form of hypertension. Uncontrolled hypertension could also, in turn, be a risk factor for a seizure threshold decrease and development of epileptogenesis. The present study aimed to assess the effects of the selective AT1 receptor antagonist ZD7155 on kainic acid (KA)-induced status epilepticus (SE) development and accompanying changes in the hippocampal extracellular (EC) neurotransmitter levels of noradrenaline (NAD), serotonin (5-HT), and dopamine (DA) in spontaneously hypertensive rats (SHRs) and their parent strain Wistar-Kyoto (WKY) rats, since monoamines are well-known neurotransmitters involved in mechanisms of both epilepsy and hypertension. Status epilepticus was evoked in freely moving rats by a repetitive intraperitoneal (i.p.) administration of KA in subconvulsant doses. In the treatment group, ZD7155 (5mg/kg i.p.) was coadministered with the first KA injection. Spontaneously hypertensive rats exhibited higher susceptibility to SE than WKY rats, but the AT1 receptor antagonist did not alter the development of SE in SHRs or in WKY rats. In vivo microdialysis demonstrated significant KA-induced increases of the hippocampal NAD and DA levels in SHRs and of NAD, 5-HT, and DA in WKY rats. Although SHRs developed more severe seizures while receiving a lower dose of KA compared to WKY rats, AT1 receptor antagonism completely prevented all KA-induced increases of hippocampal monoamine levels in both rat strains without affecting seizure development per se. These results suggest a lack of direct relationship between KA-induced seizure susceptibility and adaptive changes of hippocampal NAD, 5-HT, and DA levels in the effects of ZD7155 in WKY rats and SHRs.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AT(1) receptor antagonist; Kainate-induced status epilepticus; Monoamines; Spontaneously hypertensive rats

Mesh:

Substances:

Year:  2015        PMID: 25922088     DOI: 10.1016/j.yebeh.2015.03.021

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  4 in total

1.  Thalamic dopaminergic neurons projects to the paraventricular nucleus-rostral ventrolateral medulla/C1 neural circuit.

Authors:  Olalekan M Ogundele; Charles C Lee; Joseph Francis
Journal:  Anat Rec (Hoboken)       Date:  2017-04-10       Impact factor: 2.064

Review 2.  The Potential Therapeutic Capacity of Inhibiting the Brain Renin-Angiotensin System in the Treatment of Co-Morbid Conditions in Epilepsy.

Authors:  Natasha Ivanova; Jana Tchekalarova
Journal:  CNS Drugs       Date:  2019-11       Impact factor: 5.749

3.  Hypertension, seizures, and epilepsy: a review on pathophysiology and management.

Authors:  Sara Gasparini; Edoardo Ferlazzo; Chiara Sueri; Vittoria Cianci; Michele Ascoli; Salvatore M Cavalli; Ettore Beghi; Vincenzo Belcastro; Amedeo Bianchi; Paolo Benna; Roberto Cantello; Domenico Consoli; Fabrizio A De Falco; Giancarlo Di Gennaro; Antonio Gambardella; Gian Luigi Gigli; Alfonso Iudice; Angelo Labate; Roberto Michelucci; Maurizio Paciaroni; Pasquale Palumbo; Alberto Primavera; Ferdinando Sartucci; Pasquale Striano; Flavio Villani; Emilio Russo; Giovambattista De Sarro; Umberto Aguglia
Journal:  Neurol Sci       Date:  2019-05-04       Impact factor: 3.307

Review 4.  Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs.

Authors:  Dubravka Svob Strac; Nela Pivac; Ilse J Smolders; Wieslawa A Fogel; Philippe De Deurwaerdere; Giuseppe Di Giovanni
Journal:  Front Neurosci       Date:  2016-11-10       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.